Oncology
Myelofibrosis
Expert Roundtables Podcast: Targeting Anemia and Thrombocytopenia in Myelofibrosis
Al-Ali HK, Kuykendall AT, Ellis CE, Sampath J, Mesa R. Anemia in myelofibrosis: a focus on proactive management and the role of momelotinib. Cancers (Basel). 2024;16(23):4064. doi:10.3390/cancers16234064
Mascarenhas J. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol. 2022;15(8):671-684. doi:10.1080/17474086.2022.2112565
Naymagon L, Mascarenhas J. Myelofibrosis-related anemia: current and emerging therapeutic strategies. Hemasphere. 2017;1(1):e1. doi:10.1097/HS9.0000000000000001
Reynolds SB, Komrokji R, Kuykendall AT. The ongoing challenges of managing cytopenic myelofibrosis in 2025: the emergence of non-JAK inhibitor therapies. Blood Lymphat Cancer. 2025;15:181-192. doi:10.2147/BLCTT.S549533
Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):801-821. doi:10.1002/ajh.26857
Tucker N. Integrating prognostic risk score into the diagnosis and treatment of patients with MPNs. Targeted Oncology. October 15, 2021. Accessed December 2, 2025. https://www.targetedonc.com/view/integrating-prognostic-risk-score-into-the-diagnosis-and-treatment-of-patients-with-mpns



